CAJ | 학술논문

目的：观察拉米夫定联合阿德福韦酯治疗慢性乙型肝炎患者的临床疗效及安全性。方法：选取2008年1月到2011年12月收治的HBeAg阳性慢性乙型肝炎患者110例，分组为单药组和联合组，单药组服用拉米夫定100 mg/d，联合组服用拉米夫定100 mg/d和阿德福韦酯10 mg/d，观察两组患者治疗96周的疗效及不良反应。结果：治疗96周后，联合组的HBV-DNA应答率、ALT复常率、HBeAg阴转率、HBeAg血清学转换率分别为96.4％、94.5％、61.8％和41.9％，远高于单药组的72.7％、83.7％、45.3％和34?5％( P<0.05)，两组治疗期间仅见轻度不良反应。单药组出现12例病毒学突破，联合组未见。结论：HBeAg阳性的慢性乙型肝炎患者，使用拉米夫定联合阿德福韦酯治疗可以提高临床疗效，降低病毒耐药率，具有良好的安全性。
목적：관찰랍미부정연합아덕복위지치료만성을형간염환자적림상료효급안전성。방법：선취2008년1월도2011년12월수치적HBeAg양성만성을형간염환자110례，분조위단약조화연합조，단약조복용랍미부정100 mg/d，연합조복용랍미부정100 mg/d화아덕복위지10 mg/d，관찰량조환자치료96주적료효급불량반응。결과：치료96주후，연합조적HBV-DNA응답솔、ALT복상솔、HBeAg음전솔、HBeAg혈청학전환솔분별위96.4％、94.5％、61.8％화41.9％，원고우단약조적72.7％、83.7％、45.3％화34?5％( P<0.05)，량조치료기간부견경도불량반응。단약조출현12례병독학돌파，연합조미견。결론：HBeAg양성적만성을형간염환자，사용랍미부정연합아덕복위지치료가이제고림상료효，강저병독내약솔，구유량호적안전성。
Objective:To investigate the efficacy and safety of lamivudine ( LAM ) plus adefovir dipivoxil ( ADV) on HBeAg-positive chronic hepatitis B ( CHB) . Methods:Between January 2008 and December 2011,we recruited 110 patients with chronic hepatitis B who were assigned to receive LAM 100mg/d alone ( monotherapy group) or in combination with ADV 10mg/d ( treatment group) for 96 weeks. This was followed by assessment of the efficacy and adverse reaction at week 96. Results: After 96-week treatment, the combination treatment group yielded markedly higher responsiveness rate of HBV DNA (96.4% vs 72.7%),the recovery rate of ALT (94.5% vs 83.7%),the negativity of HBeAg (61.8% vs 45.3%) and the seroconversion rate of HBeAg (41.9% vs 34.5%) (all P<0.05). Only mild adverse reactions were found. There were 12 cases with virological breakthrough in the monotherapy group and nil case in the combination treatment group. Conclusion: The combination of LAM and ADV markedly increases the efficacy and reduces the resistant rate and is associated with high safety profiles in patients with HBeAg-positive chronic hepatitis B.